{"id":"W2242192297","doi":"10.1200/jco.2007.25.18_suppl.4031","title":"Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2<sup>nd</sup>-line treatment for patients with metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Oxaliplatin; Medicine; Capecitabine; Internal medicine; Irinotecan; FOLFOX; Fluorouracil; Regimen; Oncology; Colorectal cancer; Clinical endpoint; Folinic acid; Chemotherapy; Hazard ratio; Gastroenterology; Cancer; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002871356,0.001909173,0.002190533,0.0003837735,0.0004353304,0.001033517,0.001097664,0.001643663,0.006625468],"category_scores_gemma":[0.001599538,0.0006673154,0.001447408,0.0004063145,0.001241922,0.0009242253,0.0004277109,0.004134538,0.001223099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007656607,"about_ca_system_score_gemma":0.001564116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008751483,"about_ca_topic_score_gemma":0.002073133,"domain_scores_codex":[0.999509,0.0003011716,0.00002070735,0.00006728083,0.0000336576,0.00006820304],"domain_scores_gemma":[0.998763,0.000402127,0.0001916766,0.00008924992,0.00005429102,0.000499683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9607607,0.01694557,0.0007965546,0.0003300601,0.0005242319,0.00006867542,0.0000877108,0.0006985739,0.003794426,0.0001754448,0.001768571,0.01404962],"study_design_scores_gemma":[0.8934156,0.1026568,0.001484426,0.00002335085,0.0002244168,0.00004718716,0.00001870439,0.0007507136,0.0004800415,0.0001586039,0.0007303613,0.000009825747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843181,0.003006137,0.0007856807,0.001326969,0.000822734,0.004834293,0.001369593,0.0001393873,0.003396964],"genre_scores_gemma":[0.979102,0.002093944,0.00211978,0.002076823,0.0006502719,0.005026843,0.002281375,0.00004082375,0.006608146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006625468,"threshold_uncertainty_score":0.0221644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09282949187002007,"score_gpt":0.454005148675823,"score_spread":0.3611756568058029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}